GLPwatch
Liraglutide (Victoza) for type 2 diabetes.
Med Lett Drugs Ther · 2010
Last updated 2026-05-28Liraglutide (Victoza) is a GLP-1 drug approved by the FDA for treating type 2 diabetes, but it is not recommended as the first treatment option. It can be used alone or combined with medications like metformin or glimepiride, but it is not approved for use with insulin.
AI summary of the abstract below.
| Journal | Med Lett Drugs Ther, 2010 |
|---|---|
| Citations | 4 |
| Relative citation ratio | 0.10 |
| NIH percentile | 8 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
Liraglutide (Victoza-Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can be used alone or in addition to oral antidiabetic drugs such as metformin (Glucophage, and others) or glimepiride (Amaryl, and others). Liraglutide is not recommended for first-line therapy and is not approved for use with insulin.
Verbatim abstract via PubMed 20360660 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.